
China Pharma Secures AI Deals
Chinese pharmaceutical firms secured over $24.8 billion in out-licensing deals, shifting to high-value AI-driven innovation. This intensifies global competition for novel therapeutics, requiring R&D leaders and procurement teams to reassess pipeline strategies.
























